Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy, developed by Baylor College of Medicine, utilizes autologous adipose-derived mesenchymal stem cells (AdMSCs) for the treatment of erectile dysfunction and cardiovascular disease in aging men. The therapy involves harvesting a patient's own adipose tissue, from which MSCs are isolated and expanded ex vivo by Celltex Therapeutics Corporation. These cells are then administered via intravenous infusion every two weeks for a period of three months. The treatment aims to address endothelial dysfunction, a shared underlying pathology in both erectile and cardiac conditions, by promoting vascular repair and improving endothelial health through paracrine signaling and regenerative mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Baylor College of Medicine).